WOODCLIFF LAKE, N.J. — October 6, 2025 — Leads & Copy — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) announced today that its unaudited financial statements for the three months ended March 31, 2025, are available online.
Eagle is a fully integrated pharmaceutical company specializing in research and development, clinical trials, manufacturing, and commercialization. It focuses on developing innovative medicines for significant improvements in patient lives. Eagle’s marketed products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its subsidiary Acacia Pharma Inc. The company’s pipeline includes oncology and CNS/metabolic critical care product candidates, targeting underserved therapeutic areas and personalized medicine in cancer care.
Additional information can be found on the company’s website.
Investor Relations Contact:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eagle Pharmaceuticals, Inc.
